An archaeosome-adjuvanted vaccine and checkpoint inhibitor therapy combination significantly enhances protection from murine melanoma

From National Research Council Canada

  1. (PDF, 970 KiB)
DOIResolve DOI:
AuthorSearch for: 1; Search for: 1; Search for: 1; Search for: 1; Search for: 1; Search for: 1; Search for: 1
Name affiliation
  1. National Research Council of Canada. Human Health Therapeutics
FormatText, Article
Subjectcheckpoint inhibitor; PD-1; CTLA-4; tumor-infiltrating lymphocyte (TIL); cancer vaccine; CD8+ T cell response; archaeosome; prime-boost; B16; liposome; tumor vaccine; effector T cell (TE); effector memory T cell (TEM)
Publication date
Peer reviewedYes
NPARC number23002442
Export citationExport as RIS
Report a correctionReport a correction (opens in a new tab)
Record identifier1ff8f5a6-aba3-4909-bfa7-97e7093a9083
Record created2017-11-10
Record modified2020-05-30
Date modified: